natgillin/translations-raw huggingface dataset:
Leukopenia (including neutropenia and agranulocytosis), anaemia 
zelo pogosti levkopenija (vključno z nevtropenijo in agranulocitozo), anemija
The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind study in 46 paediatric patients (6 to 17 years old) with moderate enthesitis-related arthritis. 
Varnost in učinkovitost zdravila Humira so ocenili v multicentrični, randomizirani, dvojno slepi študiji pri 46 pediatričnih bolnikih (starih od 6 do 17 let) z zmernim artritisom, povezanim z entezitisom.
• nerve disorders (such as eye nerve inflammation and Guillain-Barré syndrome that may cause muscle weakness, abnormal sensations, tingling in the arms and upper body) 
• bolezni živčevja (kot je vnetje očesnega živca in sindrom Guillain-Barré, ki lahko povzroči šibkost mišic, nenormalna občutenja, mravljinčenje v rokah in zgornjem delu telesa)
The white needle sleeve will now be exposed. 
Zdaj je viden beli tulec igle.
• new onset or worsening of psoriasis 
• izpadanje las • pojav ali poslabšanje psoriaze
Your child should not take Humira with medicines containing the active substances anakinra or abatacept due to increased risk of serious infection. 
Zdravila Humira vaš otrok ne sme jemati z zdravili, ki vsebujejo učinkovini anakinro ali abatacept zaradi povečanega tveganja za resne okužbe.
Your doctor may recommend temporary discontinuation of Humira. 
Vaš zdravnik bo morda priporočil začasno prenehanje uporabe zdravila Humira.
Do not remove the caps until just before injection. 
Pokrovčke odstranite šele tik pred injiciranjem.
Keep this Patient Reminder Card with you. 
To opozorilno kartico za bolnika imejte pri sebi.
The following instructions explain how to inject Humira. 
Spodnja navodila pojasnjujejo, kako injicirati zdravilo Humira.
• lupus-like syndrome 
• sindrom podoben lupusu
Humira has not been studied in patients with enthesitis-related arthritis aged less than 6 years. 
Zdravila Humira niso preučevali pri bolnikih z artritisom, povezanim z entezitisom, starih manj kot 6 let.
• nerve disorders (such as eye nerve inflammation and Guillain-Barré syndrome that may cause muscle weakness, abnormal sensations, tingling in the arms and upper body); 
• bolezni živčevja (kot je vnetje očesnega živca in sindrom Guillain-Barré, ki lahko povzroči šibkost mišic, nenormalna občutenja, mravljinčenje v rokah in zgornjem delu telesa);
RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were  18 years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. 
V študiji revmatoidnega artritisa II je bilo ocenjeno 544 bolnikov z zmerno do hudo aktivnim revmatoidnim artritisom, starih ≥ 18 let, pri katerih zdravljenje z vsaj enim imunomodulirajočim antirevmatičnim zdravilom ni bilo uspešno.
Amongst those who responded at Week 16 (n=144), the Pediatric ACR 30/50/70/90 responses were maintained for up to six years in the OLE phase in patients who received Humira throughout the study. 
Med bolniki, ki so se odzvali 16. teden (n = 144), so se odzivi »Pediatric ACR« 30/50/70/90 v odprti podaljšani fazi ohranili do šest let pri tistih, ki so ves čas študije dobivali zdravilo Humira.
In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when adalimumab was used as add-on to methotrexate. 
Pri bolnikih, ki sočasno niso dobivali metotreksata, je bila incidenca 12,4 %, pri tistih, ki so adalimumab uporabljali kot dodatek metotreksatu, pa 0,6 %.
The safety and efficacy of Humira were assessed in randomised, double-blind, placebo-controlled studies and an open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS) who were intolerant, had a contraindication or an inadequate response to at least a 3-month trial of systemic antibiotic therapy. 
Varnost in učinkovitost zdravila Humira so raziskali v randomiziranih, dvojno slepih študijah, kontroliranih s placebom in v odprti podaljšani študiji pri odraslih bolnikih z zmerno do hudo obliko hidradenitis suppurativa (HS), ki imajo intoleranco, kontraindikacijo ali se ne odzovejo zadovoljivo pri vsaj 3-mesečnem preskušanju sistemske antibiotične terapije.
Humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whom corticosteroid treatment is inappropriate. 
Zdravilo Humira je indicirano za zdravljenje neinfekcijskega intermediarnega, posteriornega uveitisa in panuveitisa pri odraslih bolnikih, ki se niso zadostno odzvali na zdravljenje s kortikosteroidi, pri bolnikih s potrebo po zmanjšani uporabi kortikosteroidov ali pri bolnikih, pri katerih je zdravljenje s kortikosteroidi neprimerno.
Week 16 Placebo-Controlled 
16. teden Kontrolirana s placebom26.
All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor) while on Humira. 
Vsem bolnikom je treba naročiti, naj nemudoma poiščejo zdravniško pomoč, če se jim med uporabo zdravilaHumira pojavijo znaki ali simptomi krvnih diskrazij (npr. trajno zvišana telesna temperatura, podplutbe, krvavitve, bledica).
After 16 weeks of therapy, patients who achieved at least a PASI 75 response (PASI score improvement of at least 75% relative to baseline), entered period B and received open-label 40 mg Humira every other week. 
Po 16 tednih zdravljenja so bolniki, ki so dosegli odziv PASI vsaj 75 (izboljšanje ocene PASI za vsaj 75 % glede na izhodišče), vstopili v obdobje B, med katerim so v odprti študiji dobivali 40 mg zdravila Humira vsak drugi teden.
leflunomide and injectable gold preparations) 
hidroksiklorokinom, leflunomidom in pripravki zlata za injiciranje)
The incidence of serious infections was 0.04 per patient year in Humira treated patients and 0.03 per patient year in placebo and active control − treated patients. 
Incidenca resnih okužb je bila 0,04 na bolnikov-let med bolniki, ki so dobivali zdravilo Humira, in 0,03 na bolnikov-let med bolniki, ki so dobivali placebo oziroma kontrolno učinkovino.
Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors. 
Farmakoterapevtska skupina: Zdravila za zaviranje imunske odzivnosti, zaviralci tumorje nekrotizirajočega faktorja alfa (TNF-α), oznaka ATC: L04AB04.
Do not use this medicine after the expiry date stated on the label/blister/carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki/pretisnem omotu/škatli poleg oznake “Uporabno do”.
After treatment with Humira, a rapid decrease in levels of acute phase reactants of inflammation (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was observed, compared to baseline in patients with rheumatoid arthritis. 
Po zdravljenju z zdravilom Humira so pri bolnikih z revmatoidnim artritisom opažali hitro znižanje reaktantov akutne faze vnetja (C-reaktivnega proteina (CRP) in hitrosti sedimentacije eritrocitov (SR)) in serumskih citokinov (IL-6) v primerjavi z izhodiščem.
Patients treated with Humira usually experienced improvement in haematological signs of chronic inflammation. 
Z zdravilom Humira zdravljenim bolnikom so se ponavadi izboljšali hematološki znaki kroničnega vnetja.
You and your doctor should pay special attention to signs of infection while you are being treated with Humira. 
Vi sami in vaš zdravnik morata biti posebej pozorna na znake okužbe, medtem ko ste zdravljeni z zdravilom Humira.
Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. 
Z rentgenskim slikanjem je bilo dokazano, da zdravilo Humira upočasni hitrost napredovanja prizadetosti sklepov in izboljša telesno funkcijo, kadar se uporablja v kombinaciji z metotreksatom.
Humira has not been studied in patients with hepatic or renal impairment. 
Zdravila Humira niso proučili pri bolnikih z okvaro jeter ali ledvic.
PsA study I with 24 week duration, treated 313 adult patients who had an inadequate response to non-steroidal anti-inflammatory drug therapy and of these, approximately 50% were taking methotrexate. 
V njej so zdravili 313 odraslih, ki se niso ustrezno odzvali na terapijo z nesteroidnimi protivnetnimi zdravili; približno 50 % od teh je jemalo metotreksat.
Hidradenitis suppurativa Age or body weight 
Hidradenitis suppurativa Starost ali telesna masa
• facial oedema associated with allergic reactions; 
• edem obraza povezan z alergijskimi reakcijami;
• Do not remove the Grey or Plum-coloured Caps while allowing Humira to reach room temperature 
• Sivega ali škrlatnega pokrovčka ne odstranite dokler zdravilo Humira ne doseže sobne temperature.
Corticosteroids or other medicines that influence the immune system may be continued while using Humira. 
Kortikosteroidi ali druga zdravila, ki zavirajo imunski sistem, se lahko še nadalje uporabljajo ob uporabi zdravila Humira.
Patients who had been randomised to placebo in Period A were assigned to receive Humira 40 mg every week in Period B. 
Bolniki, ki so jih randomizirali na placebo v obdobju A, so v obdobju B prejemali zdravilo Humira 40 mg vsak teden.
The other ingredients are mannitol, polysorbate 80 and water for injections. 
Druge sestavine zdravila so manitol, polisorbat 80 in voda za injekcije.
Lift the pre-filled pen straight up from the injection site. 
Dvignite napolnjeni injekcijski peresnik navpično z mesta injiciranja.
Based on the observed data approach, 216 (80.3%) were in quiescence (no active inflammatory lesions, AC cell grade ≤ 0.5+, VH grade ≤ 0.5+) with a concomitant steroid dose ≤ 7.5 mg per day, and 178 (66.2%) were in steroid-free quiescence. 
Na osnovi pristopa z opaženimi podatki je bilo 216 (80,3 %) bolnikov v remisiji (brez aktivnih vnetnih lezij, ocena celic sprednje očesne komore ≤ 0,5+, motnost steklovine ≤ 0,5+) ob sočasnem jemanju steroidov v odmerku ≤ 7,5 mg na dan in pa 178 bolnikov (66,2 %), ki so bili v remisiji in brez steroidov.
All patients received a 2-week standardised dose of prednisone 60 mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid discontinuation by Week 15. 
Vsi bolniki so ob začetku študije prejeli 2-tedenski standardizirani odmerek prednizona 60 mg/dan, čemur je sledil obvezen program postopnega zmanjševanja, s popolno ukinitvijo kortikosteroidov do 15. tedna.
Administration of Humira should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled. 
Če se bolniku pojavi nova resna okužba ali sepsa, je treba uporabo zdravila Humira prekiniti in uvesti ustrezno protimikrobno ali protimikotično zdravljenje, dokler okužba ni obvladana.
The serum levels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in patients with measurable AAA. 
Ugotovljeno je bilo, da so koncentracije prostega adalimumaba (tistega, ki ni vezan na protitelesa proti adalimumabu) v serumu manjše pri bolnikih, ki imajo merljivo raven protiteles proti adalimumabu.
Very common 
Skupno je bilo
Humira has been shown to slow down the damage to the cartilage and bone of the joints caused by the disease and to improve physical function. 
Dokazano je, da zdravilo Humira upočasni okvaro sklepnega hrustanca in kosti, ki jo povzroča ta bolezen in izboljšuje telesno delovanje.
h MRI Sacroiliac Joints d,i 
SPARCCh MRI sakroiliakalnih sklepov d,i
Exposure-response relationships between adalimumab concentration and efficacy in paediatric patients with severe chronic plaque psoriasis were established for PASI 75 and PGA clear or minimal, respectively. 
Razmerji med izpostavljenostjo in odzivom med koncentracijo adalimumaba in učinkovitostjo pri pediatričnih bolnikih s hudo kronično psoriazo v plakih sta bili za PASI 75 (PASI - Psoriasis Area and
Contents of the pack and other information Injecting Humira 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Humira
• As cases of tuberculosis have been reported in patients treated with Humira, your doctor will check your child for signs and symptoms of tuberculosis before starting Humira. 
• Ker so bili pri bolnikih, zdravljenih z zdravilom Humira, opisani primeri tuberkuloze, bo zdravnik vašega otroka pred začetkom zdravljenja z zdravilom Humira preiskal glede znakov in simptomov tuberkuloze.
Assessment of SpondyloArthritis international Society Bath Ankylosing Spondylitis Disease Activity Index Ankylosing Spondylitis Disease Activity Score mean change from baseline n=91 placebo and n=87 Humira high sensitivity C-Reactive Protein (mg/L) n=73 placebo and n=70 Humira Spondyloarthritis Research Consortium of Canada n=84 placebo and Humira n=82 placebo and n=85 Humira ***, **, * Statistically significant at p < 0.001, < 0.01, and < 0.05, respectively, for all comparisons between Humira and placebo. 
d povprečna sprememba od začetka zdravljenja e n = 91 placebo in n = 87 zdravilo Humira f hs-CRP = C-reaktivni protein z veliko občutljivostjo (high sensitivity C-Reactive Protein) (mg/L) g n = 73 placebo in n = 70 zdravilo Humira h SPARCC = Kanadski raziskovalni konzorcij za spondiloartritis (Spondyloarthritis Research Consortium of Canada) i n = 84 placebo in zdravilo Humira j n = 82 placebo in n = 85 zdravilo Humira
• You will need a special container for waste, such as a sharps container or as instructed by your nurse, doctor or pharmacist. 
• Potrebovali boste poseben vsebnik za odpadke, kot je vsebnik za ostre predmete ali, kot so vam naročili medicinska sestra, zdravnik ali farmacevt.
Humira contains sodium 
Zdravilo Humira vsebuje natrij
Excipients with known effects 
Pomožne snovi z znanim delovanjem
• You will be instructed by your doctor, nurse or pharmacist on the technique of self-injection. 
• Zdravnik, farmacevt ali medicinska sestra vas bodo naučili, kako si zdravilo injicirate sami.
Squeeze the skin at your injection site with your other hand to make a raised area and hold it firmly until the injection is complete. 
Kožo na mestu injiciranja stisnite z drugo roko, tako da se površina dvigne, in jo držite čvrsto, dokler injiciranje ni končano.
• It is important that you tell your baby's doctors and other health care professionals about your Humira use during your pregnancy before the baby receives any vaccine (for more information on vaccines see the “Warnings and precautions” section). 
• Pomembno je, da obvestite zdravnika vašega dojenčka in druge zdravstvene delavce, da ste med nosečnostjo prejemali zdravilo Humira, preden bo vaš dojenček prejel katerokoli cepivo (za več informacij o cepljenju glejte poglavje "Opozorila in previdnostni ukrepi").
Efficacy Outcomes Double Blind 32 weeks Humira / MTX (N = 38) 
Dvojno slepa 32 tednov Zdravilo Humira / MTX (n = 38)
For storage information, see package leaflet. 
Za informacije o shranjevanju glejte navodilo za uporabo.
• diverticulitis (inflammation and infection of the large intestine) 
• divertikulitis (vnetje in okužba debelega črevesa)
Humira is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. 
Zdravilo Humira je indicirano za zdravljenje aktivnega in napredujočega psoriatičnega artritisa pri odraslih, če odziv na predhodno zdravljenje z imunomodulirajočimi antirevmatiki ni bil ustrezen.
• Do not rub • Slight bleeding at the injection site is normal 
• Rahla krvavitev na mestu injiciranja je normalna.
What the Humira vial looks like and contents of the pack 
Izgled zdravila Humira in vsebina pakiranja
No ALT elevations ≥ 3 x ULN occurred in the Phase 3 trial of Humira in patients with polyarticular juvenile idiopathic arthritis who were 2 to <4 years. 
Zvišanja ALT ≥ 3 x ULN se niso pojavila v preskušanju faze 3 z zdravilom Humira pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom, ki so bili stari od 2 do < 4 leta.
• bacterial infections 
• bakterijske okužbe
• Do not give Humira to children with polyarticular juvenile idiopathic arthritis below the age of 2 
• Zdravila Humira ne smete dati otroku s poliartikularnim juvenilnim idiopatskim artritisom, če je star manj kot 2 leti.
Keep pushing down to prevent the pre-filled pen from moving away from the skin during the injection. 
Potiskajte navzdol, da se napolnjeni injekcijski peresnik med injiciranjem ne odmakne od kože.
Following 52 weeks and 104 weeks of treatment, the percentage of patients without progression (change from baseline in modified Total Sharp Score  0.5) was significantly higher with Humira/methotrexate combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and 33.5% respectively, p < 0.001) and Humira monotherapy (50.7%, p < 0.002 and 44.5%, p < 0.001 respectively). 
Po 52 oz. 104 tednih zdravljenja je bil v skupini s kombinirano terapijo z zdravilom Humira in metotreksatom odstotek bolnikov brez napredovanja bolezni (sprememba prilagojene Sharpove ocene od izhodišča ≤ 0,5) značilno večji (63,8 % oz. 61,2 %) kot v skupinah, ki sta prejemali monoterapijo z metotreksatom (37,4 % in 33,5 %, p < 0,001) ali monoterapijo z zdravilom Humira (50,7 %, p < 0,002, oz. 44,5 %, p < 0,001).
At Week 16, a statistically significantly greater proportion of patients who received Humira achieved PGA of 'clear' or 'almost clear' for the hands and/or feet compared to patients who received placebo (30.6% versus 4.3%, respectively [P = 0.014]). 
V 16. tednu je statistično pomembno večji delež bolnikov, ki so prejemali zdravilo Humira, doseglo PGA ‘'čisto'' ali ‘'skoraj čisto'' za dlani in/ali stopala, v primerjavi z bolniki, ki so prejemali placebo
Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or other TNF-antagonists is not recommended based upon the possible increased risk for infections, including serious infections and other potential pharmacological interactions. 
Sočasna uporaba adalimumaba z drugimi biološkimi DMARDS (tj.anakinra in abacept) ali z drugimi antagonisti TNF ni priporočljiva zaradi možnega povečanega tveganja za okužbe, vključno z resnimi okužbami in drugih potencialnih farmakoloških interakcij (glejte poglavje 4.5).
Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use of Humira. 
Poročali so tudi o smrtnih in življenjsko ogrožajočih okužbah (vključno s sepso, oportunističnimi okužbami in TB), HBV reaktivaciji in različnih malignih obolenjih (vključno z levkemijo, limfomom in HSTCL).
In study UC-II, 248 patients received 160 mg of Humira at Week 0, 80 mg at Week 2 and 40 mg eow thereafter, and 246 patients received placebo. 
V študiji UC-II je 248 bolnikov dobilo 160 mg zdravila Humira 0. teden, 80 mg 2. teden in nato 40 mg vsak drugi teden, 246 bolnikov pa je dobivalo placebo.
The safety and efficacy of Humira were assessed in adult patients with non-infectious intermediate, posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, doublemasked, placebo-controlled studies (UV I and II). 
Varnost in učinkovitost zdravila Humira sta bili ocenjeni pri odraslih bolnikih z neinfekcijskim intermediarnim, posteriornim uveitisom in panuveitisom v dveh randomiziranih, dvojno slepih, s placebom kontroliranih študijah (UV I in UV II), ki nista vključevali bolnikov z izoliranim anteriornim uveitisom.
A single Humira pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. 
Posamezna napolnjena injekcijska brizga ali napolnjen injekcijski peresnik zdravila Humira se lahko shranjuje pri temperaturi največ do 25 ºC za obdobje do 14 dni.
The target of adalimumab is a protein called tumour necrosis factor (TNFα), which is involved in the immune (defence) system and is present at increased levels in the inflammatory diseases listed above. 
Tarča adalimumaba je beljakovina ki se imenuje tumor nekrotizirajoči faktor (TNF), ki je vključen v imunski (obrambni) sistem in je prisoten v povečanih koncentracijah pri zgoraj navedenih vnetnih boleznih.
• benign tumours 
• benigni tumorji
• Tuberculosis can develop during therapy even if you have received treatment for the prevention of tuberculosis. 
• Tuberkuloza se lahko razvije med zdravljenjem, tudi če ste prejeli zdravljenje za preprečevanje tuberkuloze.
Should treatment be interrupted, Humira 40 mg every week or 80 mg every other week may be reintroduced (see section 5.1). 
Če je potrebno z zdravljenjem prekiniti, lahko ponovno uvedete zdravljenje z zdravilom Humira z odmerkom 40 mg vsak teden ali 80 mg vsak drugi teden (glejte poglavje 5.1).
***, ** Statistically significant at p < 0.001 and < 0.01, respectively, for all comparisons between Humira and placebo. 
***, ** Statistično značilno pri p < 0,001 in < 0,01 (v tem zaporedju) za vse primerjave med zdravilom Humira in placebom.
Excipients: mannitol, citric acid monohydrate, sodium citrate, sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, sodium chloride, polysorbate 80, sodium hydroxide and water for injections. 
Pomožne snovi: manitol, citronska kislina monohidrat, natrijev citrat, natrijev dihidrogenfosfat dihidrat, natrijev hidrogenfosfat dihidrat, natrijev klorid, polisorbat 80, natrijev hidroksid in voda za injekcije.
Humira Dose for Paediatric Patients with Crohn's disease 
Odmerjanje zdravila Humira pri pediatričnih bolnikih s Crohnovo boleznijo
Antibody formation was lower when Humira was given together with methotrexate in comparison with use as monotherapy. 
Če je bilo zdravilo Humira uporabljeno skupaj z metotreksatom, je bilo nastajanje protiteles v primerjavi z monoterapijo manjše.
In people who carry HBV, Humira can cause the virus to become active again. 
Zdravilo Humira lahko pri nosilcih HBV povzroči, da virus znova postane aktiven.
Patients taking TNF-antagonists are more susceptible to serious infections. 
Okužbe Bolniki, ki uporabljajo antagoniste tumor nekrotizirajočega faktorja (TNF), so bolj dovzetni za resne okužbe.
For the pooled crossover RA studies VI and VII, a statistically significant difference for injection site pain immediately after dosing was observed between Humira 40 mg/0.8 ml and Humira 40 mg/0.4 ml (mean VAS of 3.7 cm versus 1.2 cm, scale of 0-10 cm, P < 0.001). 
Pri združenih navzkrižnih študijah revmatoidnega artritisa VI in VII, so opazili statistično pomembne razlike pri bolečini na mestu injiciranja takoj po injiciranju med zdravilom Humira 40 mg/0,8 ml in zdravilom Humira 40 mg/0,4 ml (povprečna vrednost na vizualni analogni lestvici 3,7 cm, v primerjavi z 1,2 cm, na lestvici od 0 do10 cm, p <0,001).
Your child's symptoms may return upon discontinuation. 
Simptomi vašega otroka se lahko po prekinitvi zdravljenja povrnejo.
• inflammation of the skin (such as eczema) 
• vnetje kože (kot je ekcem)
The other ingredients are mannitol, citric acid monohydrate, sodium citrate, sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, sodium chloride, polysorbate 80, sodium hydroxide and water for injections. 
Druge sestavine zdravila so manitol, citronska kislina monohidrat, natrijev citrat, natrijev dihidrogenfosfat dihidrat, natrijev hidrogenfosfat dihidrat, natrijev klorid, polisorbat 80, natrijev hidroksid in voda za injekcije.
Table 18: 
Preglednica 16:
There is insufficient evidence of the efficacy of Humira in patients with ankylosing spondylitis-like psoriatic arthropathy due to the small number of patients studied. 
Zaradi majhnega števila bolnikov ni dovolj dokazov o učinkovitosti zdravila Humira pri bolnikih s psoriatično artropatijo, podobno ankilozirajočemu spondilitisu.